Physician profile
Jay Gottlieb
NPI 1588660757
$4,560.99
in general payments reported to CMS, 2019-2025
26 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $228 · 2021: $683 · 2022: $468 · 2023: $803 · 2024: $977 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.84 |
| Education | $111.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $823.57 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $634.23 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $556.48 | 2019-2025 | |
| Genzyme Corporation | $509.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $476.45 | 2019-2025 | |
| Pfizer INC. | $250.24 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $150.52 | 2019-2024 | Winlevi, Absorica Ld |
| Almirall LLC | $120.22 | 2019-2022 | |
| Galderma Laboratories, L.P. | $115.96 | 2019-2025 | Nemluvio |
| Ucb, INC. | $114.12 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $112.73 | 2022-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.50 | 2020-2023 | Arazlo, Jublia |
| Strata Skin Sciences, INC. | $74.68 | 2020-2023 | Xtrac |
| Allergan, INC. | $71.60 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.71 | 2020-2024 | Otezla |
| Biofrontera INC. | $59.45 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $55.76 | 2021-2023 | |
| Leo Pharma INC. | $52.40 | 2019-2023 | Adbry |
| Verrica Pharmaceuticals INC. | $31.79 | 2023 | Ycanth |
| Incyte Corporation | $24.27 | 2023 | Opzelura |
| Lnhc, INC | $20.58 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $20.23 | 2023 | |
| Celgene Corporation | $20.11 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.22 | 2021 | |
| Mylan Pharmaceuticals INC. | $15.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.